| Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single‐cell transcriptomics SM Tirier, JP Mallm, S Steiger, AM Poos, MHS Awwad, N Giesen, ... Nature Communications 12 (1), 6960, 2021 | 105 | 2021 |
| Pathway-directed therapy in multiple myeloma L John, MT Krauth, K Podar, MS Raab Cancers 13 (7), 1668, 2021 | 44 | 2021 |
| Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level C Schinke, AM Poos, M Bauer, L John, S Johnson, S Deshpande, ... Blood Advances 6 (22), 5873-5883, 2022 | 34 | 2022 |
| Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis AM Poos, N Prokoph, MJ Przybilla, JP Mallm, S Steiger, I Seufert, L John, ... Blood 142 (19), 1633-1646, 2023 | 30 | 2023 |
| Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level L John, AM Poos, A Brobeil, C Schinke, S Huhn, N Prokoph, R Lutz, ... Nature Communications 14 (1), 5011, 2023 | 21 | 2023 |
| Application of an artificial intelligence-based tool in [18F]FDG PET/CT for the assessment of bone marrow involvement in multiple myeloma C Sachpekidis, O Enqvist, J Ulén, A Kopp-Schneider, L Pan, A Jauch, ... European Journal of Nuclear Medicine and Molecular Imaging 50 (12), 3697-3708, 2023 | 16 | 2023 |
| The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma AM Cirrincione, AM Poos, B Ziccheddu, M Kaddoura, MA Baertsch, ... Blood Journal, blood. 2024024299, 2024 | 8 | 2024 |
| Comprehensive comparison of early relapse and end-stage relapsed refractory multiple myeloma AM Poos, N Giesen, C Catalano, N Paramasivam, D Huebschmann, ... Blood 136, 1, 2020 | 7 | 2020 |
| Idecabtagene Vicleucel Is Well Tolerated and Effective in Relapsed/Refractory Myeloma Patients with Prior Allogeneic Stem Cell Transplantation L John, S Sauer, U Hegenbart, P Dreger, M Hundemer, C Müller-Tidow, ... Transplantation and Cellular Therapy 29 (10), 609. e1-609. e6, 2023 | 5 | 2023 |
| Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant P Langer, L John, I Monsef, C Scheid, V Piechotta, N Skoetz Cochrane Database of Systematic Reviews, 2024 | 4 | 2024 |
| Bone marrow immune signatures in multiple myeloma are linked to tumor heterogeneity and treatment outcome S Steiger, R Lutz, N Prokoph, S Palit, SM Tirier, P Reichert, A Baumann, ... Blood 140 (Supplement 1), 2083-2085, 2022 | 4 | 2022 |
| Midkine promotes metastasis and therapeutic resistance via mTOR/RPS6 in uveal melanoma MM Karg, L John, N Refaian, C Buettner, T Rottmar, J Sommer, B Bock, ... Molecular Cancer Research 20 (8), 1320-1336, 2022 | 3 | 2022 |
| The spatial heterogeneity in newly diagnosed multiple myeloma patients-from sub-clonal architecture to the immune microenvironment L John, A Poos, SM Tirier, JP Mallm, N Prokoph, A Brobeil, R Lutz, ... Blood 138, 729, 2021 | 3 | 2021 |
| Efficacy and safety of daratumumab for the treatment of multiple myeloma: a series of Cochrane reviews C Hirsch, V Piechotta, P Langer, C Scheid, L John, N Skoetz Hematological Oncology 39, 2021 | 3 | 2021 |
| A Comprehensive Analysis of Single-Cell Chromatin Accessibility and Gene Expression Identifies Intra-Tumor Heterogeneity and Molecular Treatment Responses in Relapsed … AM Poos, JP Mallm, SM Tirier, N Casiraghi, H Susak, N Giesen, K Bauer, ... Blood 134, 575, 2019 | 3 | 2019 |
| Clinical and serological characterization of acute pleuropericarditis suggests an autoinflammatory pathogenesis and highlights risk factors for recurrent attacks D Kaudewitz, L John, J Meis, N Frey, HM Lorenz, F Leuschner, N Blank Clinical Research in Cardiology, 1-9, 2024 | 2 | 2024 |
| Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma L John, K Miah, A Benner, EK Mai, K Kriegsmann, M Hundemer, ... Frontiers in Oncology 13, 1078725, 2023 | 2 | 2023 |
| Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma AL Grab, PS Kim, L John, K Bisht, H Wang, A Baumann, H Van de Velde, ... Cells 13 (10), 879, 2024 | 1 | 2024 |
| Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple Myeloma F Maura, MA Kaddoura, A Poos, L Baughn, B Ziccheddu, MA Bartsch, ... bioRxiv, 2024.08. 30.610457, 2024 | 1 | 2024 |
| OA-23 Resolving therapy resistance mechanisms in multiple myeloma by multi-omics subclone analysis A Poos, N Prokoph, M Przybilla, JP Mallm, S Steiger, I Seufert, L John, ... Clinical Lymphoma Myeloma and Leukemia 23, S14-S15, 2023 | 1 | 2023 |
